We are conducting a new clinical trial for people with Eosinophilic Esophagitis (EoE). The clinical trial is investigating tezepelumab – an investigational antibody drug. Tezepelumab has a new and unique action in the body. It stops a chemical produced in the body called thymic stromal lymphopoietin (TSLP). TSLP is increased in some people with EoE and causes inflammation. By blocking TSLP, researchers believe that tezepelumab will reduce inflammation in the esophagus and improve swallowing symptoms for patients with EoE.

You may be eligible to participate if you:

• Are 12 – 80 years old
• Have a diagnosis of EoE confirmed by an upper endoscopy (EGD) and esophageal biopsy
• Weigh at least 40 kg (88.2 lbs.)
• Have an average of at least 2 episodes of swallowing difficulties (dysphagia) per week.

There are additional criteria to meet to qualify for this study. Volunteers who qualify for our study will receive study-related medication and study-related medical exams at no cost and a stipend for time and travel. No health insurance is required to participate.

For more information call

(904) 680-0871

Or sign up below, and our friendly staff will call you!

We are conducting a new clinical trial for people with Eosinophilic Esophagitis (EoE). The clinical trial is investigating tezepelumab – an investigational antibody drug. Tezepelumab has a new and unique action in the body. It stops a chemical produced in the body called thymic stromal lymphopoietin (TSLP). TSLP is increased in some people with EoE and causes inflammation. By blocking TSLP, researchers believe that tezepelumab will reduce inflammation in the esophagus and improve swallowing symptoms for patients with EoE.

You may be eligible to participate if you:

• Are 12 – 80 years old
• Have a diagnosis of EoE confirmed by an upper endoscopy (EGD) and esophageal biopsy
• Weigh at least 40 kg (88.2 lbs.)
• Have an average of at least 2 episodes of swallowing difficulties (dysphagia) per week.

There are additional criteria to meet to qualify for this study. Volunteers who qualify for our study will receive study-related medication and study-related medical exams at no cost and a stipend for time and travel. No health insurance is required to participate.

For more information call

(904) 209-0043

Or sign up below, and our friendly staff will call you!

We are conducting a new clinical trial for people with Eosinophilic Esophagitis (EoE). The clinical trial is investigating tezepelumab – an investigational antibody drug. Tezepelumab has a new and unique action in the body. It stops a chemical produced in the body called thymic stromal lymphopoietin (TSLP). TSLP is increased in some people with EoE and causes inflammation. By blocking TSLP, researchers believe that tezepelumab will reduce inflammation in the esophagus and improve swallowing symptoms for patients with EoE.

You may be eligible to participate if you:

• Are 12 – 80 years old
• Have a diagnosis of EoE confirmed by an upper endoscopy (EGD) and esophageal biopsy
• Weigh at least 40 kg (88.2 lbs.)
• Have an average of at least 2 episodes of swallowing difficulties (dysphagia) per week.

There are additional criteria to meet to qualify for this study. Volunteers who qualify for our study will receive study-related medication and study-related medical exams at no cost and a stipend for time and travel. No health insurance is required to participate.

For more information call

(352) 341-2100

Or sign up below, and our friendly staff will call you!

We are conducting a clinical trial for people who have active EoE.

This study will evaluate an investigational drug in adults with EoE to see how it reacts with a group of enzymes in the body called CYP (also known as cytochrome P450) that break down drugs.

The drug-drug interaction study will examine if there are any changes in CYP activity when the study drug and 5 selected approved drugs are given together. The study drug is a biologic agent, called a monoclonal antibody, and will be administered once a week for 17 weeks during the study.

This study will also evaluate whether the study drug helps the symptoms of EoE, such as trouble swallowing.

You may be eligible to participate if you:

• Are 18 – 75 years old
• Weigh at least 40 kg (88.2 lbs.)
• Have a diagnosis of eosinophilic esophagitis and active symptoms
• Are willing and able to receive weekly injections
• Used or are using proton-pump inhibitor medications but still have symptoms (these are medications used for EoE, heartburn, or indigestion, such as omeprazole [Prilosec], lansoprazole [Prevacid], esomeprazole [Nexium])

Volunteers must be able to complete some overnight stays at our clinic for this study. There are additional criteria to meet to qualify for this study. Volunteers who qualify for our study will receive study-related medication and study-related medical exams at no cost. Study participants receive payment for each study visit they attend to reimburse for their time.  No health insurance is required to participate.

 For more information call

(352) 341-2100

Or sign up below, and our friendly staff will call you!